Financials data is unavailable for this security.
View more
Year on year Ascletis Pharma Inc grew revenues 4.63% from 54.09m to 56.60m while net income improved from a loss of 314.84m to a smaller loss of 144.72m.
Gross margin | -125.17% |
---|---|
Net profit margin | -2,561.69% |
Operating margin | -2,412.67% |
Return on assets | -10.47% |
---|---|
Return on equity | -10.88% |
Return on investment | -10.85% |
More ▼
Cash flow in CNYView more
In 2023, cash reserves at Ascletis Pharma Inc fell by 73.65m. However, Cash Flow from Investing totalled 149.85m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 144.16m for operations while cash used for financing totalled 81.50m.
Cash flow per share | -0.2531 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 2.37 |
---|---|
Tangible book value per share | 2.35 |
More ▼
Balance sheet in CNYView more
Current ratio | 24.38 |
---|---|
Quick ratio | 24.31 |
Total debt/total equity | 0.0041 |
---|---|
Total debt/total capital | 0.004 |
More ▼